We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Aflibercept

News List

2024 Medical Breakthroughs: New Hope to Patients Shruti Talashi
April 11, 2024
The pharmaceutical industry is set for a major shake-up in 2024.
Ocular Therapeutix Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases firstwordpharma
August 06, 2021
Ocular Therapeutix, Inc. (NASDAQ:OCUL) today announced that Regeneron has terminated the option and license agreement collaboration between the companies.
Cipla takes deal route with Alvotech to enter Australian autoimmune biosimilars market: GlobalData expresspharma
March 22, 2021
Australia continues to focus on reducing healthcare expenditure and encouraging the use of biosimilars over their reference product.
Novartis Reports Positive Topline Results from Beovu for Diabetic Macular Edema americanpharmaceuticalreview
September 21, 2020
Novartis reported the first interpretable results of the Phase III KITE study, assessing the efficacy and safety of Beovu® (brolucizumab) 6 mg in diabetic macular edema (DME).